Demography and patient’s characteristics
| . | Median . | IQR . | Range . |
|---|---|---|---|
| Age at diagnosis, y | 74 | 65-80 | 51-87 |
| Sex, male/female | 6/6 | ||
| Initial bleeding site,*n | |||
| Skin hematomas | 12 | ||
| Deep muscle hematoma (psoas) | 5 | ||
| Superficial muscle | 10 | ||
| Retroperitoneal | 1 | ||
| Surgical wound | 6 | ||
| Hematuria | 1 | ||
| Mucosal bleeding | 2 | ||
| Joint bleedings | 1 | ||
| Central nervous system | 0 | ||
| Gastrointestinal bleeding | 0 | ||
| Trigger of bleeding,*n | |||
| None (spontaneous) | 11 | ||
| Surgery | 6 | ||
| Severity of bleeding | |||
| Severe | 8 | ||
| Mild | 4 | ||
| Time bleeding to diagnosis, d | 4 | 3-6 | 1-36 |
| Medical history,*n | |||
| None | 0 | ||
| Chronic inflammatory bowel disease | 1 | ||
| Metabolic syndrome, adiposity, diabetes | 6 | ||
| Infection, inflammation | 2 | ||
| Vascular disease (heart, peripheral, stroke) | 6 | ||
| Malignant disease | 3 | ||
| Lung disease | 4 | ||
| Psychiatric disorder | 5 | ||
| Initial FVIII activity, % | <1 | <1-1.5 | <1-11 |
| Maximum inhibitor titer, BU/mL | 22.3 | 9-80 | 3.5-2000 |
| Maximum anti-FVIII IgG, AU/mL | 720 | 393-935 | 138-3108 |
| . | Median . | IQR . | Range . |
|---|---|---|---|
| Age at diagnosis, y | 74 | 65-80 | 51-87 |
| Sex, male/female | 6/6 | ||
| Initial bleeding site,*n | |||
| Skin hematomas | 12 | ||
| Deep muscle hematoma (psoas) | 5 | ||
| Superficial muscle | 10 | ||
| Retroperitoneal | 1 | ||
| Surgical wound | 6 | ||
| Hematuria | 1 | ||
| Mucosal bleeding | 2 | ||
| Joint bleedings | 1 | ||
| Central nervous system | 0 | ||
| Gastrointestinal bleeding | 0 | ||
| Trigger of bleeding,*n | |||
| None (spontaneous) | 11 | ||
| Surgery | 6 | ||
| Severity of bleeding | |||
| Severe | 8 | ||
| Mild | 4 | ||
| Time bleeding to diagnosis, d | 4 | 3-6 | 1-36 |
| Medical history,*n | |||
| None | 0 | ||
| Chronic inflammatory bowel disease | 1 | ||
| Metabolic syndrome, adiposity, diabetes | 6 | ||
| Infection, inflammation | 2 | ||
| Vascular disease (heart, peripheral, stroke) | 6 | ||
| Malignant disease | 3 | ||
| Lung disease | 4 | ||
| Psychiatric disorder | 5 | ||
| Initial FVIII activity, % | <1 | <1-1.5 | <1-11 |
| Maximum inhibitor titer, BU/mL | 22.3 | 9-80 | 3.5-2000 |
| Maximum anti-FVIII IgG, AU/mL | 720 | 393-935 | 138-3108 |
n = 12.
AU, arbitrary unit; BU, Bethesda unit; IQR, interquartile range.
Some patients had >1 condition.